← Back to Clinical Trials
Recruiting NCT06265103

NCT06265103 Epilepsy Learning Healthcare System (ELHS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06265103
Status Recruiting
Phase
Sponsor Epilepsy Foundation of America
Condition Epilepsy
Study Type OBSERVATIONAL
Enrollment 100,000 participants
Start Date 2019-03-20
Primary Completion 2099-02-14

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Clinical care and quality improvement

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100,000 participants in total. It began in 2019-03-20 with a primary completion date of 2099-02-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The Epilepsy Learning Health System (ELHS) is a quality improvement and research network to improve outcomes for people with epilepsy. The ELHS is designed as a model of value-based chronic care for epilepsy as envisioned by the National Academies of Medicine Committee in their landmark reports "The Learning Health System" and "Epilepsy Across the Spectrum: Promoting Health and Understanding". The ELHS network is a collaboration among clinicians, patients and researchers that promotes the use of data for multiple purposes including one-on-one clinical care, population management, quality improvement and research. The ELHS Registry includes data on children and adults with epilepsy collected during the process of standard epilepsy care. These data are used to create population health reports and to track changes in outcomes over time. ELHS teams use quality improvement methods, such as Plan-Do-Study-Act (PDSA) cycles, to continuously learn how to improve care.

Eligibility Criteria

Inclusion Criteria: * In order to be eligible to participate in this registry-based study, an individual must meet all of the following criteria: * Patient is in an established care relationship with the ELHS site Exclusion Criteria: * An individual who meets any of the following criteria will be excluded from participation in this registry-based research study: * Patients who are not currently in nor expect to be in an established care relationship with the ELHS site (for example, patients who are being seen at the center for a second opinion only). * Patients who do not, after diagnostic evaluation, meet criteria for a diagnosis of epilepsy will not be analyzed in epilepsy-specific population groups. However, these non-epilepsy patients will not be excluded from the registry.

Contact & Investigator

Central Contact

Brandy E Fureman, PhD

✉ bfureman@efa.org

📞 2404767127

Principal Investigator

Brandy Fureman, PhD

PRINCIPAL INVESTIGATOR

Epilepsy Foundation

Frequently Asked Questions

Who can join the NCT06265103 clinical trial?

This trial is open to participants of all sexes, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06265103 currently recruiting?

Yes, NCT06265103 is actively recruiting participants. Contact the research team at bfureman@efa.org for enrollment information.

Where is the NCT06265103 trial being conducted?

This trial is being conducted at Phoenix, United States, Los Angeles, United States, Los Angeles, United States, Aurora, United States and 9 additional locations.

Who is sponsoring the NCT06265103 clinical trial?

NCT06265103 is sponsored by Epilepsy Foundation of America. The principal investigator is Brandy Fureman, PhD at Epilepsy Foundation. The trial plans to enroll 100,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology